Asset Details
Do you wish to reserve the book?
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Do you wish to request the book?
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy
2012
Overview
In two trials, the addition of tiotropium to the treatment of patients whose asthma was not controlled by inhaled glucocorticoids and long-acting beta-agonists led to a modest improvement in lung function and a decrease in severe asthma exacerbations over 48 weeks.
A substantial proportion of patients with asthma have poorly controlled disease, with recurring symptoms and exacerbations despite the use of preferred controller drugs (i.e., inhaled glucocorticoids with or without inhaled long-acting beta-agonists [LABAs]). For these patients, alternative treatment options may have substantial limitations, including marginal efficacy, cumbersome routes of administration, side effects, and high cost.
1
,
2
The option of adding a second long-acting inhaled bronchodilator in patients with uncontrolled asthma has been supported by results from recent studies that examined the efficacy of tiotropium, a long-acting anticholinergic bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) but not . . .
Publisher
Massachusetts Medical Society
Subject
/ Adrenergic beta-Agonists - therapeutic use
/ Adult
/ Aged
/ Asthma
/ Biological and medical sciences
/ Bronchodilator Agents - adverse effects
/ Bronchodilator Agents - therapeutic use
/ Chronic obstructive pulmonary disease
/ Chronic obstructive pulmonary disease, asthma
/ Female
/ Glucocorticoids - therapeutic use
/ Humans
/ Male
/ Patients
/ Scopolamine Derivatives - adverse effects
